Amgen’s Future Looks Brighter After Ruling Lifts Threat Of Enbrel Copycat

 
• By Sten Stovall

Markets are re-assessing Amgen’s long-term value after a US judge upheld two patents relating to Amgen's blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis and allowing investors to focus now on the pharma’s promising pipeline.

Gates
US court ruling upheld two patents Underpinning Amgen's blockbuster Enbrel • Source: Shutterstock

More from Business

More from Scrip